Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Behandeling stadium II-III niet-kleincellig longcarcinoom gaat flink op de schop
apr 2024 | Immuuntherapie, Longoncologie